Cytokinetics Secures MHRA Marketing Authorization For MYQORZO In OHCM
Cytokinetics (CYTK) said the UK MHRA granted marketing authorization for MYQORZO (aficamten) to treat adults with obstructive hypertrophic cardiomyopathy, NYHA class II-III. NICE issued positive guidance for eligible patients in England and Wales. Approval cited SEQUOIA-HCM Phase 3 results, with peak oxygen uptake improving vs placebo (1.8 vs 0.0 mL/kg/min, p<0.001).
How this was made
The 30-second read
Why it matters
MHRA marketing authorization for NYHA II-III oHCM and concurrent NICE positive guidance reduce regulatory and access uncertainty in the UK, supporting commercialization expectations for aficamten.
Market read
This is a UK commercialization milestone for CYTK’s aficamten, supported by MHRA authorization and NICE guidance, with availability expected later this year.
What to watch
The article does not quantify expected UK sales, reimbursement rates, or competitive dynamics versus other oHCM options, which are key for valuation.
Background
MYQORZO (aficamten) is a cardiac myosin inhibitor being developed for obstructive hypertrophic cardiomyopathy (oHCM).
Ticker impact
Cytokinetics said MHRA granted marketing authorization for MYQORZO (aficamten) for NYHA II-III obstructive HCM, with NICE positive guidance in England and Wales.
Likely supportive for CYTK shares, with follow-through dependent on UK launch timing and payer uptake later this year.
The article reports first-time UK marketing authorization and positive NICE guidance, both of which reduce regulatory and access risk. It does not provide financial terms, uptake metrics, or broader EU/US catalysts, limiting magnitude.
Market effects
Strengthens the cardiac myosin inhibitor narrative and may increase investor attention on late-stage cardiomyopathy therapeutics and payer access pathways.
Improves UK treatment access prospects for obstructive HCM, potentially accelerating adoption among eligible NHS patients.
Adds to the global regulatory momentum for aficamten, though the article is UK-specific.
Counterpoint
Approval does not guarantee rapid uptake; real-world prescribing and NHS commissioning decisions could lag, limiting near-term revenue impact.
Key entities
- companyCytokinetics, Incorporated
Developer of MYQORZO (aficamten) for obstructive hypertrophic cardiomyopathy.
- drugMYQORZO (aficamten)
Cardiac myosin inhibitor for adult patients with obstructive hypertrophic cardiomyopathy, NYHA II-III.
- regulatorMHRA
UK Medicines and Healthcare products Regulatory Agency that granted marketing authorization.
- health technology assessment bodyNICE
Issued positive guidance recommending aficamten for eligible patients in England and Wales.
- clinical trialSEQUOIA-HCM
Phase 3 study (282 adults) cited as the basis for MHRA review, showing improved peak oxygen uptake vs placebo.
